522 related articles for article (PubMed ID: 25900105)
21. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
Padula WV; Ballreich J; Anderson GF
Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
[TBL] [Abstract][Full Text] [Related]
22. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
23. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
Dusetzina SB; Conti RM; Yu NL; Bach PB
JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
[TBL] [Abstract][Full Text] [Related]
24. Time trends in medication use and expenditures in older patients with rheumatoid arthritis.
Harrold LR; Peterson D; Beard AJ; Gurwitz JH; Briesacher BA
Am J Med; 2012 Sep; 125(9):937.e9-15. PubMed ID: 22682794
[TBL] [Abstract][Full Text] [Related]
25. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
26. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
Zhang J; Xie F; Delzell E; Chen L; Kilgore ML; Yun H; Saag KG; Lewis JD; Curtis JR
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1743-51. PubMed ID: 23754804
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
28. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
29. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
30. Effect of cost sharing on prescription drug use by Medicare beneficiaries prior to the Medicare Drug Benefit and potential adverse selection in the benefit.
Goedken AM; Urmie JM; Farris KB; Doucette WR
J Am Pharm Assoc (2003); 2009; 49(1):18-25. PubMed ID: 19196592
[TBL] [Abstract][Full Text] [Related]
31. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
32. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
[TBL] [Abstract][Full Text] [Related]
33. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.
Atzinger CB; Guo JJ
Am Health Drug Benefits; 2017 Feb; 10(1):27-36. PubMed ID: 28465766
[TBL] [Abstract][Full Text] [Related]
34. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
35. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
36. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
McWilliams JM; Zaslavsky AM; Huskamp HA
JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
[TBL] [Abstract][Full Text] [Related]
37. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
[TBL] [Abstract][Full Text] [Related]
38. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
39. Medicare part d and the federal employees health benefits program: a comparison of prescription drug coverage.
Lovett A
Am Health Drug Benefits; 2013 Jan; 6(1):47-58. PubMed ID: 24991346
[TBL] [Abstract][Full Text] [Related]
40. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]